been reports of seizures in patients with or without a history of seizures, treated with Varenicline. Having a seizure affects your legal ability to drive. If you have a seizure and do not stop driving you may be breaking the law, your current driving licence may not be valid and your vehicle insurance may not cover you. Following a seizure, drivers of certain categories of vehicles may have to stop driving for a minimum of five years. 11. Upon stopping treatment with varenicline, patients may experience an increase in irritability, urge to smoke, depression and/or insomnia. This can occur in up to 3% of patients. Pharmacists can refer to the SPC for varenicline for more detailed information. The very common (> 1 in 10; and common effects > 1 in 100) are: Identification and Very Common - Abnormal dreams, insomnia, Headache, nausea management of Common - Increased appetite, Somnolence, dizziness, dysgeusia, adverse reactions Vomiting, constipation, diarrhoea, abdominal distension, stomach discomfort, dyspepsia, flatulence, dry mouth, fatigue Seizures are an uncommon side-effect. Varenicline is a all adverse reactions ‘black triangle’ drug. Therefore Reporting procedure should be reported to the CSM using the reporting system ‘Yellow Card’ for adverse reactions A copy of this PGD Access to latest Summary of Product Characteristics for varenicline (available at www.medicines.org.uk) Supplies and resources that must Latest version of the British National Formulary be available at sites Information about services involved in providing healthy lifestyles where this PGD is in use It is the responsibility of the individual pharmacist to ensure that they and their staff are competent in all aspects of the supply of varenicline and are updated on current medicines policies. Pharmacists must satisfy themselves on that the patient is still eligible to receive treatment with varenicline at each supply. This Ongoing supplies of should include a re-examination of the exclusion criteria such as varenicline recent onset of depressive symptoms. Additional Facilities Consulting Room See Appendix 1 for all documentation and protocol date of birth and GP details; Patient’s name, address, Date supplied & Name of the pharmacist who supplied the Records to be kept for medication; legal and audit purposes Start date and Quit date; Batch number and expiry date; Quantity supplied and dose advised
been reports of seizures in patients with or without a history of seizures, treated with Varenicline. Having a seizure affects your legal ability to drive. If you have a seizure and do not stop driving you may be breaking the law, your current driving licence may not be valid and your vehicle insurance may not cover you. Following a seizure, drivers of certain categories of vehicles may have to stop driving for a minimum of five years. 11. Upon stopping treatment with varenicline, patients may experience an increase in irritability, urge to smoke, depression and/or insomnia. This can occur in up to 3% of patients. Identification and management of adverse reactions Pharmacists can refer to the SPC for varenicline for more detailed information. The very common (> 1 in 10; and common effects > 1 in 100) are: Very Common - Abnormal dreams, insomnia, Headache, nausea Common - Increased appetite, Somnolence, dizziness, dysgeusia, Vomiting, constipation, diarrhoea, abdominal distension, stomach discomfort, dyspepsia, flatulence, dry mouth, fatigue Seizures are an uncommon side-effect. Reporting procedure for adverse reactions Varenicline is a ‘black triangle’ drug. Therefore all adverse reactions should be reported to the CSM using the ‘Yellow Card’ reporting system Supplies and resources that must be available at sites where this PGD is in use A copy of this PGD Access to latest Summary of Product Characteristics for varenicline (available at www.medicines.org.uk) Latest version of the British National Formulary Information about services involved in providing healthy lifestyles It is the responsibility of the individual pharmacist to ensure that they and their staff are competent in all aspects of the supply of varenicline and are updated on current medicines policies. Ongoing supplies of varenicline Pharmacists must satisfy themselves on that the patient is still eligible to receive treatment with varenicline at each supply. This should include a re-examination of the exclusion criteria such as recent onset of depressive symptoms. Additional Facilities Consulting Room Records to be kept for legal and audit purposes See Appendix 1 for all documentation and protocol Patient’s name, address, date of birth and GP details; Date supplied & Name of the pharmacist who supplied the medication; Start date and Quit date; Batch number and expiry date; Quantity supplied and dose advised
Final-2015-16-Pharmacy-Stop-Smoking-Service-Specification-.docx